Zobrazeno 1 - 10
of 23
pro vyhledávání: '"SIDDHARTH KUNTE"'
Autor:
Mohammadhadi Khorrami, Vidya Sakar Viswanathan, Priyanka Reddy, Nathaniel Braman, Siddharth Kunte, Amit Gupta, Jame Abraham, Alberto J. Montero, Anant Madabhushi
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract The combination of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard of care for hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
Externí odkaz:
https://doaj.org/article/f997f48cfd63439786061cd76e2b42ae
Autor:
Roger S. Smith, Igor Odintsov, Zebing Liu, Allan Jo-Weng Lui, Takuo Hayashi, Morana Vojnic, Yoshiyuki Suehara, Lukas Delasos, Marissa S. Mattar, Julija Hmeljak, Hillary A. Ramirez, Melissa Shaw, Gabrielle Bui, Alifiani B. Hartono, Eric Gladstone, Siddharth Kunte, Heather Magnan, Inna Khodos, Elisa De Stanchina, Michael P. La Quaglia, Jinjuan Yao, Marick Laé, Sean B. Lee, Lee Spraggon, Christine A. Pratilas, Marc Ladanyi, Romel Somwar
Publikováno v:
Disease Models & Mechanisms, Vol 15, Iss 1 (2022)
Desmoplastic small round cell tumor (DSRCT) is characterized by the t(11;22)(p13;q12) translocation, which fuses the transcriptional regulatory domain of EWSR1 with the DNA-binding domain of WT1, resulting in the oncogenic EWSR1-WT1 fusion protein. T
Externí odkaz:
https://doaj.org/article/7b83f47a6c8e4d5eb829d9ab77a3d402
Autor:
Takuo Hayashi, Igor Odintsov, Roger S. Smith, Kota Ishizawa, Allan J. W. Liu, Lukas Delasos, Christopher Kurzatkowski, Huichun Tai, Eric Gladstone, Morana Vojnic, Shinji Kohsaka, Ken Suzawa, Zebing Liu, Siddharth Kunte, Marissa S. Mattar, Inna Khodos, Monika A. Davare, Alexander Drilon, Emily Cheng, Elisa de Stanchina, Marc Ladanyi, Romel Somwar
Publikováno v:
Disease Models & Mechanisms, Vol 14, Iss 2 (2021)
Multi-kinase RET inhibitors, such as cabozantinib and RXDX-105, are active in lung cancer patients with RET fusions; however, the overall response rates to these two drugs are unsatisfactory compared to other targeted therapy paradigms. Moreover, the
Externí odkaz:
https://doaj.org/article/2e7e848718f248f5b1b70bad579df39d
Autor:
Veronica Mariotti, David B. Page, Oksana Davydov, Didier Hans, Clifford A. Hudis, Sujata Patil, Siddharth Kunte, Monica Girotra, Azeez Farooki, Monica N. Fornier
Publikováno v:
Journal of Bone Oncology, Vol 7, Iss C, Pp 32-37 (2017)
Introduction: Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor positive breast carcinoma, and are known to induce bone density loss and increase the risk of fractures. The current standard-of-care screening
Externí odkaz:
https://doaj.org/article/1b98a1d4536a4a2384fe89b89ca5f1d3
Autor:
Vidya Sankar Viswanathan, Nathaniel Braman, Priyanka Reddy, Siddharth Kunte, Jame Abraham, Alberto J Montero, Anant Madabhushi
Publikováno v:
Cancer Research. 82:P5-13
Background: CDK 4/6 inhibitors (CDKI) with Endocrine therapy (ET) is mainstay treatment for hormone receptor-positive (HR+) Her2- metastatic breast cancer (MBC). Despite excellent efficacy, most patients develop resistance to CDKI limiting its utilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::757f590b1c2624368d8c3f9e1d4b5b29
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-27
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-27
Autor:
Amy E. DeZern, Bhagirathbhai Dholaria, Richard J. Jones, Vikas Gupta, Siddharth Kunte, Asad Bashey, Aaron T. Gerds, Anurag K. Singh, Michael R. Grunwald, Roni Tamari, Michael Ozga, Hany Elmariah, Auro Viswabandya, Lisa Rybicki, Alla Keyzner, Madiha Iqbal, Sameem Abedin, Tania Jain
Publikováno v:
Leukemia
We report the results from a multicenter retrospective study of 69 adult patients who underwent haploidentical blood or marrow transplantation (haplo-BMT) with post-transplantation cyclophosphamide (PTCy) for chronic phase myelofibrosis. The median a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51441f7a52b7eeb8bb029a59b3c5f7a0
https://doi.org/10.1038/s41375-021-01449-1
https://doi.org/10.1038/s41375-021-01449-1
Autor:
Anant Madabhushi, Mohammadhadi Khorrami, Vidya Viswanathan, Priyanka Reddy, Nathaniel Braman, Siddharth Kunte, Amit Gupta, Jame Abraham, Alberto Montero
Background The combination of Cyclin-dependent kinase 4/6 inhibitors (CDKi) and endocrine therapy (ET) is the standard of care for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c201b385218818365465b5fb1dd7d1ef
https://doi.org/10.21203/rs.3.rs-2002969/v1
https://doi.org/10.21203/rs.3.rs-2002969/v1
Publikováno v:
Cancer Research. 81:PS5-42
Background: CDK 4/6 inhibitors are currently standard of care for patients CDK 4/6 inhibitors but currently lack validated predictive markers. We evaluated whether changes in intra-lesional heterogeneity, extracted computationally from routine comput
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::506f578776cb3dd4fa2f02a9efb431a8
https://doi.org/10.1158/1538-7445.sabcs20-ps5-42
https://doi.org/10.1158/1538-7445.sabcs20-ps5-42
Publikováno v:
Cancer. 126:4278-4288
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% of all breast cancers. Before the development of HER2-directed monoclonal antibodies, HER2-positive breast cancer was associated with a rather poor prognosis. With
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af9fa2530632be55f9bfbd4b184c9eb0
https://doi.org/10.1002/cncr.33102
https://doi.org/10.1002/cncr.33102
Autor:
SIDDHARTH KUNTE, JONATHAN SHARETT, WEI WEI, CHRISTIAN NASR, BRANDON PRENDES, ERIC LAMARRE, JAMIE KU, ROBERT R. LORENZ, JOSEPH SCHARPF, BRIAN B. BURKEY, AKEESHA SHAH, NIKHIL JOSHI, JESSICA L. GEIGER
Publikováno v:
Anticancer research. 42(5)
Poorly differentiated thyroid cancer (PDTC) is a rare but aggressive subtype of thyroid cancer that portends a poor prognosis. There remains a paucity of literature on PDTC outcomes. The aim of our study was to evaluate outcomes of PDTC in our tertia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cd0bbb52475a061d85c7b4832a1b5c2
https://pubmed.ncbi.nlm.nih.gov/35489769
https://pubmed.ncbi.nlm.nih.gov/35489769